Evidence map›Paper›PMID 22622808›Full record

ArticleBreast cancer research and treatment2012

Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter.

V Bartella, P Rizza, I Barone, D Zito, F Giordano, C Giordano, S Catalano, L Mauro, D Sisci, M L Panno and 2 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Cure and Long-Term Remission Strategies.Methods in molecular biology (Clifton, N.J.) · 2022
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

V BartellaDepartment of Pharmaco-Biology, University of Calabria, Via P. Bucci, 87036 Arcavacata di Rende, CS, Italy.
P Rizza
I Barone
D Zito
F Giordano
C Giordano
S Catalano
L Mauro
D Sisci
M L Panno
S A W Fuqua
S Andò
University of Calabria · ITBaylor College of Medicine · US

Funding

Replication Stress and DNA Damage Response Drives ESR1 Mutant MetastasisR01CA072038 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI Suzanne AW Fuqua · 1996 to 2026
$6.7M
NCI NIH HHS R01 CA072038NCI NIH HHS R01 CA72038
6 · The paper itself

Abstract

Human estrogen receptors alpha and beta are crucially involved in the regulation of mammary growth and development. Normal breast tissues display a relative higher expression of ER beta than ER alpha, which drastically changes during breast tumorogenesis. Thus, it is reasonable to suggest that a dysregulation of the two estrogen receptor subtypes may induce breast cancer development. However, the molecular mechanisms underlying the potential opposing roles played by the two estrogen receptors on tumor cell growth remain to be elucidated. In the present study, we have demonstrated that ER beta overexpression in breast cancer cells decreases cell proliferation and down-regulates ER alpha mRNA and protein content, along with a concomitant repression of estrogen-regulated genes. Transient transfection experiments, using a vector containing the human ER alpha promoter region, showed that elevated levels of ER beta down-regulated basal ER alpha promoter activity. Furthermore, site-directed mutagenesis and deletion analysis revealed that the proximal GC-rich motifs at -223 and -214 are critical for the ER beta-induced ER alpha down-regulation in breast cancer cells. This occurred through ER beta-Sp1 protein-protein interactions within the ER alpha promoter region and the recruitment of a corepressor complex containing the nuclear receptor corepressor NCoR, accompanied by hypoacetylation of histone H4 and displacement of RNA-polymerase II. Silencing of NCoR gene expression by RNA interference reversed the down-regulatory effects of ER beta on ER alpha gene expression and cell proliferation. Our results provide evidence for a novel mechanism by which overexpression of ER beta through NCoR is able to down regulate ER alpha gene expression, thus blocking ER alpha's driving role on breast cancer cell growth.

Indexed as

Response ElementsBreast NeoplasmsCell Line, TumorCell ProliferationChromatin ImmunoprecipitationEstrogen Receptor alphaEstrogen Receptor betaFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansInsulin-Like Growth Factor INuclear Receptor Co-Repressor 1Promoter Regions, GeneticProtein BindingRNA InterferenceESR1 protein, humanEstrogen Receptor alphaEstrogen Receptor betaInsulin-Like Growth Factor INCOR1 protein, humanNuclear Receptor Co-Repressor 1RNA Polymerase IISp1 Transcription Factor

Identifiers

PMID22622808
PMCPMC4484599
OpenAlexW2095797462

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.